Loss of heterozygosity on chromosome 6p21.2 as a potential marker for recurrence after radiotherapy of human cervical cancer

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1079-1085

  Harima, Yoko ^a   Harima, Keizo ^a   Sawada, Satoshi ^a   Tanaka, Yoshimasa ^a   Arita, Seizaburo ^a   Ohnishi, Takeo ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 6P; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 6; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0034062223     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Pontén, J., Adami, H. O., Bergström, R., Dillner, J., Friberg, L. G., Gustafsson, L., Miller, A, B., Parkin, D. M., Sparen, P., and Trichopoulos, D. Strategies for global control of cervical cancer. Int. J. Cancer, 60: 1-26, 1995.
2. Virostek, L. J., Kim, R. Y., Spencer, S. A, Meredith, R. F., Jennelle, R. L., Soong, S. J., and Salter, M. M. Postsurgical recurrent carcinoma of the cervix: reassessment and results of radiation therapy options. Radiology, 201: 559-563, 1996.
3. Ogawara, K., Miyakawa, A., Shiba, M., Uzawa, K., Watanabe, T., Wang, X. L., Sato, T., Kubosawa, H., Kondo, Y., and Tanzawa, H. Allelic loss of chromosome 13q14.3 in human oral cancer: correlation with lymph node metastasis. Int. J. Cancer, 79: 312-317, 1998.
4. Petersen, S., Wolf, G., Bockmuhl, U., Gellert, K., Dietel, M., and Petersen, I. Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype. Br. J. Cancer, 77: 270-276, 1998.
5. Karnik, P., Paris, M., Williams, B. R., Casey, G., Crowe, J., and Chen, P. Two distinct tumor suppressor loci within chromosome 11p15 implicated in breast cancer progression and metastasis. Hum. Mol. Genet., 7: 895-903, 1998.
6. Atkin, N. B., Baker, M. C., and Fox, M. F. Chromosome changes in 43 carcinomas of the cervix uteri. Cancer Genet. Cytogenet., 44: 229-241, 1990.
7. Yokota, J., Mori, N., Akiyama, T., Shimosato, Y., Sugimura, T., and Terada, M. Multiple genetic alterations in small-cell lung carcinoma. Princess Takamatsu Symp., 20: 43-48, 1989.
8. Jones, M. H., and Nakamura, Y. Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene, 7: 1631-1634, 1992.
9. Kohno, T., Takayama, H., Hamaguchi, M., Takano, H., Yamaguchi, N., Tsuda, H., Hirohashi, S., Vissing, H., Shimizu, M., Oshimura, M., and Yokota, J. Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene, 8: 1825-1832, 1993.
10. Mitra, A. B., Murty, V. V., Singh, V., Li, R. G., Pratap, M., Sodhani, P., Luthra, U. K., and Chaganti, R. S. Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J. Natl. Cancer Inst., 87: 742-745, 1995.
11. Jones, M. H., Koi, S., Fujimoto, I., Hasumi, K., Kato, K., and Nakamura, Y. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: frequent loss of heterozygosity on chromosome arms 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer, 9: 119-123, 1994.
12. Mitra, A. B., Murty, V. V., Li, R. G., Pratap, M., Luthra, U. K., and Chaganti, R. S. Allelotype analysis of cervical carcinoma. Cancer Res., 54: 4481-4487, 1994.
13. Mullokandov, M. R., Kholodilov, N. G., Atkin, N. B., Burk, R. D., Johnson, A. B., and Klinger, H. P. Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. Cancer Res., 56: 197-205, 1996.
14. Harima, Y., Shirahama, S., Harima, K., Aoki, S., Ohnishi, T., and Tanaka, Y. Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer. Br. J. Cancer, 81: 108-113, 1999.
15. Kersemaekers, A. M., Kenter, G. G., Hermans, J., Fleuren, G. J., and van-de-Vijver, M. J. Allelic loss and prognosis in carcinoma of the uterine cervix. Int. J. Cancer, 79: 411-417, 1998.
16. Rader, J. S, Kamarasova, T., Huettner, P. C., Li, L., Li, Y., and Gerhard, D. S. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene, 13: 2737-2741, 1996.
17. Kersemaekers, A. M., Hermans, J., Fleuren, G. J., and van-de-Vijver, M. J. Loss of heterozygosity for defined regions on chromosomes 3, 11 and 17 in carcinomas of the uterine cervix. Br. J. Cancer, 77: 192-200, 1998.
18. International Federation of Gynecologists and Obstetricians. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am. J. Obstet. Gynecol., 156: 263-264, 1987.
19. ICRU Report No. 38. Dose and volume specification for reporting intracavitary therapy in gynecology, pp. 1-16. Bethesda, MD: International Commission of Radiation Units and Measurements, 1985.
20. Bauer, H., Greer, C., and Manos, M. Detection of genital human papillomavirus infection using PCR. In: C. S. Herrington and J. O. McGee (eds.), Diagnostic Molecular Pathology: A Practical Approach, pp. 131-152. Oxford: Oxford University Press, 1992.
21. Yoshikawa, H., Kawana, T., Kitagawa, K., Mizuno, M., Yoshikura, H., and Iwamoto, A. Amplification and typing of multiple cervical cancer-associated human papillomavirus DNAs using a single pair of primers. Int. J. Cancer, 45: 990-992, 1990.
22. Chen, T. M., Chen, C. A., Hsieh, C. Y., Chang, D. Y., Chen, Y. U., and Defendi, V. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells. Oncogene, 5: 1511-1518, 1993.
23. Dib, C., Faure, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Hazan, J., Seboun, E., Lathrop, M., Gyapay, G., Morissette, J., and Weissenbach, J. A comprehensive genetic map of the human genome based on 5,264 microsateilite. Nature (Lond.), 380: 152-154, 1996.
24. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
25. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
26. Patel, F. D., Sharman, S. C., Negi, P. S., Ghoshal, S., and Gupta, B. D. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int. J. Radiat. Oncol. Biol. Phys., 28: 335-341, 1993.
27. Teshima, T., Inoue, T., Ikeda, H., Miyata, Y., Nishiyama, K., Inoue, T., Murayama, S., Yamasaki, H., and Kozuka, T. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix. Final results of Osaka University Hospital. Cancer (Phila.), 72: 2409-2414, 1993.
28. Vogelstein, B., Fearon, E. R., Kern, S. E., Hamilton, S. R., Preisinger, A. C., Nakamura, Y., and White, R. Allelotype of colorectal carcinomas. Science (Washington DC), 244: 207-211, 1989.
29. Lukeis, R., Irving, L., Garson, M., and Hasthorpe, S. Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer, 2: 116-124, 1990.
30. Sato, T., Saito, H., Morita, R., Koi, S., Lee, J. H., and Nakamura, Y. Allelotype of human ovarian cancer. Cancer Res., 51: 5118-5122, 1991.
31. Morita, R., Ishikawa, J., Tsutsumi, M., Hikiji, K., Tsukada, Y., Kamidono, S., Maeda, S., and Nakamura, Y. Allelotype of renal cell carcinoma. Cancer Res., 57: 820-823, 1991.
32. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
33. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
34. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kasten, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W., and Vogelstein, B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
35. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S. J., and Reed, S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76: 1013-1023, 1994.
36. Bhatia, K., Fan, S., Spangler, G., Weintraub, M., O'Connor, P. M., Judde, J. G., and Magrath, I. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res., 55: 1431-1435, 1995.
37. Gao, X., Chen, Y. Q., Wu, N., Grignon, D. J., Sakr, W., Porter, A. T., and Honn, K. V. Somatic mutations of the WAF1/C1P1 gene in primary prostate cancer. Oncogene, 11: 1395-1398, 1995.
38. Mckenzie, K. E., Siva, A., Maier, S., Runnebaum, I. B., Seshadri, R., and Sukumar, S. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations. Clin. Cancer Res., 3: 1669-1673, 1997.
39. Shiohara, M., el-Deiry, W. S., Wada, M., Nakamaki, T., Takeuchi, S., Yang, R., Chen, D. L., Vogelstein, B., and Koeffler, H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood, 84: 3781-3784, 1994.
40. Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., and Stern, P. L. Natural history of HLA expression during tumour development. Immunol. Today, 14: 491-499, 1993.
41. Enlund, F., Samuelsson, L., Enerback, C., Inerot, A., Wahlstrom, J., Yhr, M., Torinsson, A., Martinsson, T., and Swanbeck, G. Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of familles: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. Hum. Hered., 49: 2-8, 1999.
42. Chang, F., SyrjΣnen, S., and SyrjΣnen, K. Implications of the p53 tumor-suppressor gene in clinical oncology. J. Clin. Oncol., 13: 1009-1022, 1995.
43. Aas, T., Borresen, A. L., Geisler, S., Smith-Sorensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., and Lonning, P. E. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med., 2: 811-814, 1996.
44. Ahnen, D. J., Feigl, P., Quan, G., Fenoglio-Preiser, C., Lovato, L. C., Bunn, P. A., Jr., Stemmerman, G., Wells, J. D., MacDonald, J. S., and Meyskens, F. L., Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res., 58: 1149-1158, 1998.
45. Park, D. J., Wilczynski, S. P., Paquette, R. L., Miller, C. W., and Koeffler, H. P. p53 mutations in HPV-negative cervical carcinoma. Oncogene, 9: 205-210, 1994.
46. zur Hausen, H., and de Villier, E. Human papillomavirus. Annu. Rev. Microbiol., 48: 427-447, 1994.
47. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.
48. Butz, K., Shahabeddin, L., Geisen, C., Spitkovsky, D., Ullmann, A., and Hoppe-Seyler, F. Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene, 10: 927-936, 1995.
49. King, L. A., Tase, T., Twiggs, L. B., Okagaki, T., Savage, J. E., Adcock, L. L., Prem, K. A., and Carson, L. F. Prognostic significance of the presence of human papillomavirus DNA in patients with invasive carcinoma of the cervix. Cancer (Phila.), 63: 897-900, 1989.
50. Higgins, G. D., Davy, M., Roder, D., Uzelin, D. M., Phillips, G. E., and Burrell, C. J. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet, 338: 910-913, 1991.
51. Kapp, D. S., and Giaccia, A. New direction for radiation biology research in cancer of the uterine cervix. J. Natl. Cancer Inst., 27; 131-138, 1996.
52. Kristensen, G. B., Karlsen, F., Jenkins, A., Kaern, J., Abeler, V. M., and Trope, C. G. Human papilloma virus has no prognostic significance in cervical carcinoma. Eur. J. Cancer, 32: 1349-1353, 1996.
53. Burger, R. A., Monk, B. J., Kurosaki, T., Anton-Culver, H., Vasilev, S. A., Berman, M. L., and Wilczynski, S. P. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J. Natl. Cancer Inst., 88: 1361-1368, 1996.
54. Matsumoto, K., Yoshikawa, H., Taketani, Y., Yoshiike, K., and Kanda, T. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn. J. Cancer Res., 88; 369-375, 1997.
55. Kawana, T. Human papilloma virus and cervical cancer. Jpn. J. Cancer Chemother., 22; 711-717, 1995.
56. Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L., and Insalaco, S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med., 340: 1144-1153, 1999.
57. Morris, M., Eifel, P. J., Lu, J., Grigsby, P. W., Levenback, C., Stevens, R. E., Rotman, M., Gershenson, D. M., and Mutch, D. G. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med., 340: 1137-1143, 1999.